Protagonist's rusfertide clearance unlocks $275m from Takeda; company announces $300m buyback

Protagonist Therapeutics said on 5 November that regulatory success for its lead programmes has materially strengthened its finances. In its third-quarter 2026 update, the company pointed to the US Food and Drug Administration's 28 August approval of MIMRYLO (rusfertide), which it developed with Takeda, for erythrocytosis in adults with polycythemia vera.

The company said that approval set off payments of $275 million from Takeda. Protagonist closed the period with $834.6 million in cash and announced a $300 million share repurchase. The information available does not give the buyback's structure, timetable or funding, nor quarterly revenue or earnings figures, so the net effect of the Takeda money on the income statement cannot be assessed here.

Protagonist also reported progress outside the US for icotrokinra, branded ICOTYDE, in psoriasis. The product has now been approved in China, Japan and the European Union, which broadens the markets where it can be sold in that indication.

Missing from the update are details on pricing, reimbursement and launch timing for either product, and the split of Takeda's payments between the milestones that were triggered. Those will shape how quickly the approvals turn into recurring sales.